APPLICATION OF NANOPARTICLES TO TREAT INFECTIONS IN THE RESPIRATORY TRACT
A method of using nanoparticle (NP) spray to treat an infection in the respiratory system and far infrared radiation (FIR) to treat inflammation. The method uses a spray probe inserted into the airway of a patient to apply mSiO 2 and FIR to a target site in the upper respiratory tract. FIR applied may be in the 3-10 μm range. The mSiO 2 spray kills any organisms, including COVID-19 and FIR reduces inflammation resulting from infection. The treatment may be applied to intubated or spontaneously breathing patients and via the oral or nasal passages.
1 . A method of treating a respiratory infection comprising the steps of:
introducing at least one probe into an airway of a patient;
advancing the at least one probe to a target site; and
activating the at least one probe such that the at least one probe applies nanoparticles to the target site.
2 . A method of treating a respiratory infection as in claim 1 , further comprising the steps of activating the at least one probe such that the at least one probe emits far infrared radiation (FIR).
3 . A method of treating a respiratory infection as in claim 2 , wherein the FIR emitted is in the 3-10 μm range.
4 . A method of treating a respiratory infection as in claim 1 , wherein the nanoparticles are silica based.
5 . A method of treating a respiratory infection as in claim 4 , wherein the nanoparticles are mesoporous silica nanoparticles.
6 . A method of treating a respiratory infection as in claim 2 wherein the step of activating the at least one probe such that the at least one probe emits FIR is performed after the step of activating the at least one probe such that the at least one probe applies nanoparticles to the target site.
7 . A method of treating a respiratory infection as in claim 1 , wherein the nanoparticles are administered at a concentration up to 10 −5 g mL −1 .
8 . A method of treating a respiratory infection as in claim 1 , further comprising the step of applying nanoparticles within the airway for a duration of 1-4 hours.
9 . A method of treating a respiratory infection as in claim 1 , wherein the step of activating the at least one probe such that the at least one probe applies nanoparticles to the target, destroys COVID-19 viral particles at the target site.
10 . A method of treating a respiratory infection, comprising the steps of:
positioning a probe within a trachea or another part of the respiratory system of a mammalian patient so that a portion of the probe configured to spray nanoparticles is at or near the location of a virus causing the respiratory infection;
operating the probe to apply nanoparticles at or near the location of the virus causing the nanoparticles to destroy some or all of the virus.
11 . A method of treating a respiratory infection as in claim 10 , wherein the portion of the probe configured to spray nanoparticles is also configured to emit FIR and the method further comprises the step of operating the probe to emit FIR.
12 . A method of treating a respiratory infection as in claim 11 , wherein the step of operating the probe to emit FIR is performed after the step of operating the probe to apply nanoparticles.
13 . A method of treating a respiratory infection as in claim 11 , wherein the nanoparticles are administered at a concentration of up to 10 −5 g mL −1 .
14 . A method of treating a respiratory infection as in claim 13 , wherein the nanoparticles are applied for a duration of 1-4 hours.
15 . A method of treating a respiratory infection as in claim 13 , wherein the nanoparticles are silica based.
16 . A method of treating a respiratory infection as in claim 15 , wherein the nanoparticles are mesoporous silica nanoparticles.
17 . A method of treating a respiratory infection as in claim 11 , further comprising the step of rotating the portion of the probe configured to apply nanoparticles and configured to emit FIR while the probe is operated to apply nanoparticles and FIR.
18 . A system for treating a respiratory infection comprising:
nanoparticles; and
at least one probe configured to traverse the airway of a infected patient and configured to apply nanoparticles to a target site from a distal end of the at least one probe.
19 . A system for treating a respiratory infection as in claim 18 , further comprising a FIR source and wherein the at least one probe is operably connected to the FIR source and configured to emit FIR generated by the FIR source.
20 . A system for treating a respiratory infection as in claim 18 , wherein the at least one probe comprises a single probe configured to emit FIR and apply nanoparticles.